Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$136.06 USD
+1.81 (1.35%)
Updated Oct 17, 2025 04:00 PM ET
After-Market: $136.03 -0.03 (-0.02%) 6:50 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
JAZZ 136.06 +1.81(1.35%)
Will JAZZ be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
Can Auvelity Drive Axsome's Growth Through the Rest of 2025?
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why JAZZ Stock Is an Unconventional Cannabis Investment
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
Other News for JAZZ
3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street
First Week of June 2026 Options Trading For Jazz Pharmaceuticals (JAZZ)
JAZZ falls 1.14% on October 16, leaving the technical picture intact
Jazz Pharmaceuticals Completes Study on Promising HER2 Cancer Treatment
Is JAZZ positioned for a breakout? 20 Day Moving Average Support shows up after climbing 1.49%